Name: Buy Lixisenatide Research Peptide Online | Research Peptides Supplies
SKU: RPS-LIXISENATIDE
Price: 44.99 USD
Availability: InStock

Lixisenatide Research Peptide — Scientific Overview

Lixisenatide is a synthetic 44-amino-acid GLP-1 receptor agonist derived from exendin-4 (like exenatide), modified by deletion of one proline and addition of 6 lysines at the C-terminus. These C-terminal lysines improve affinity for the GLP-1 receptor. Lixisenatide (Adlyxin®, developed by Sanofi) received FDA approval in 2016 for Type 2 diabetes. It is characterized as a short-acting GLP-1 agonist (once-daily administration) with particularly potent effects on post-prandial glucose excursions and gastric emptying. Lixisenatide’s strong gastric emptying inhibition makes it distinctive among GLP-1 receptor agonists — it significantly delays gastric emptying, which blunts the rate of carbohydrate absorption and reduces post-prandial glucose excursions. This mechanism is particularly studied in the context of combination with basal insulin therapy (iGlarLixi) and in research models examining gastric motility biology and the interplay between GI physiology and glycemic regulation. The ELIXA cardiovascular outcomes trial (n=6,068) showed neutral CV effects — neither benefit nor harm.

Research Background

Lixisenatide’s strong gastric emptying inhibition makes it distinctive among GLP-1 receptor agonists — it significantly delays gastric emptying, which blunts the rate of carbohydrate absorption and reduces post-prandial glucose excursions. This mechanism is particularly studied in the context of combination with basal insulin therapy (iGlarLixi) and in research models examining gastric motility biology and the interplay between GI physiology and glycemic regulation. The ELIXA cardiovascular outcomes trial (n=6,068) showed neutral CV effects — neither benefit nor harm.

Key Research Areas

Post-Prandial Glucose Research: Gastric emptying inhibition and meal-related glucose excursion studies
GLP-1R Pharmacology Research: Short-acting GLP-1R agonism and receptor internalization kinetics
Gastric Motility Research: Gastric emptying rate modulation and GI physiology studies
Combination Therapy Research: Basal insulin + GLP-1 agonist combination effects in metabolic models
β-Cell Research: Glucose-dependent insulin secretion and β-cell protection biology
Comparative Pharmacology: Short-acting vs. long-acting GLP-1 agonist mechanism comparison

Technical Specifications

Parameter	Value
Sequence	Exendin-4-derived, 44 AA with 6 C-terminal lysines
Molecular Weight	~4858 Da
Purity	≥98% (HPLC-verified)
Form	Lyophilized powder, sealed under argon
Storage	−20°C (long-term)
Documentation	Batch-specific COA (HPLC + Mass Spec)

Storage & Handling (Research Laboratories)

Lyophilized Lixisenatide should be stored at −20°C for long-term preservation, protected from light and moisture. For short-term active research use, 4°C storage is acceptable for up to approximately 4 weeks. Minimize repeated freeze-thaw cycles. Follow standard laboratory peptide reconstitution and handling protocols for all experimental use.

Frequently Asked Questions — Lixisenatide Research

What distinguishes short-acting from long-acting GLP-1 receptor agonists in research?

Short-acting GLP-1 agonists (exenatide BID, lixisenatide) produce peak receptor activation shortly after administration and clear relatively quickly, resulting in prominent post-prandial glucose lowering due to strong gastric emptying inhibition. Long-acting agonists (liraglutide, dulaglutide, semaglutide) maintain near-continuous receptor occupancy, producing sustained appetite suppression and fasting glucose lowering but less pronounced gastric emptying effects (receptor desensitization reduces this effect over time). Research models use this distinction to study time-dependent GLP-1R pharmacology and the contribution of gastric emptying to glucose homeostasis.

Why does Lixisenatide have six C-terminal lysines?

The six C-terminal lysine additions in Lixisenatide were made to increase the peptide’s binding affinity to the GLP-1 receptor and to extend its effective duration at the receptor. Lysine residues are positively charged, and the C-terminal region of GLP-1 agonists contributes to secondary interactions with the receptor that influence binding kinetics. The six-lysine tail improves receptor affinity and contributes to Lixisenatide’s potent post-prandial glucose-lowering profile. This structural modification is unique among approved GLP-1 agonists.

What gastric motility research has been conducted with Lixisenatide?

GLP-1 receptor activation in the gastrointestinal tract inhibits gastric emptying through both central (vagal) and peripheral (local GI nerve) mechanisms. Lixisenatide, as a potent short-acting GLP-1R agonist, has been used as a research tool to study gastric emptying inhibition kinetics in both rodent and human research models. Radiolabeled gastric emptying studies have documented significant delays in gastric emptying with lixisenatide, with the kinetics differing from long-acting GLP-1 agonists — making it useful for dose-response and mechanism studies of GI GLP-1R physiology.

Is Lixisenatide approved for human use?

Yes — Lixisenatide (Adlyxin®) is FDA-approved for Type 2 diabetes. Research Peptides Supplies supplies it as a research-use reference standard for qualified laboratory research. Not for human administration outside approved clinical settings.

What documentation comes with Lixisenatide?

Lixisenatide from Research Peptides Supplies is verified at ≥98% purity by HPLC, with identity confirmed by Mass Spectrometry confirming the correct 44-amino-acid sequence. A batch-specific COA is provided with every order.

⚗️ Research Use Only: This product is strictly intended for qualified laboratory and scientific research use by trained professionals in appropriate laboratory settings. It is not intended for human or veterinary administration, therapeutic use, food supplement applications, or any use outside controlled research environments. Not for human consumption.